Nurix Therapeutics (NRIX) Stock Price, Quote, News & History | Benzinga

SPY770.95+0.25%QQQ723.52+0.82%BTC/USD84,536.61+1.93%DIA524.64+0.05%GLD378.32+0.18%TLT80.11−0.03%

Nurix Therapeutics Inc (NRIX) Stock Price, Quote, News & History

NRIXNASDAQ

Trade with Public

Trade with Public

$26.18

0.080.31%

Last update: Oct 21, 11:20 AM

$26.11

0.010.04%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$26.00

Close

-

Volume / Avg.

616.69K / 1.52M

Day Range

$25.80 - $26.30

52 Wk Range

9.93 - 28.23

Market Cap

$2.86B

P/E Ratio

10.74

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

16.33%

Days to Cover

9.94

Recent Nurix Therapeutics, Inc. News

SpaceX To Rally Around 85%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts raised targets for MSTR, FOXA, NRIX, ZETA and TWLO, while cutting targets for CAMT and DVN.

Avi Kapoor

Stock Market: Will S&P 500 Open Up or Down Today?

Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields, potential Iran strikes, and Pepsi earnings.

Rishabh Mishra

Top 3 Health Care Stocks That May Keep You Up At Night In June

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.

Avi Kapoor

Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research raises CLF PT.

Avi Kapoor

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market

Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

379.31M

Investing Cash Flow (TTM)

1.10M

Financing Cash Flow (TTM)

261.21M

Free Cash Flow (TTM)

369.81M

Capital Expenditure (TTM)

-9.50M

Net Change in Cash (TTM)

641.62M

Analyst Trends and Forecast

8

Jun

9

Jul

2

Aug

6

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.87B

PE Ratio (TTM)

10.74

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

4.07

PB Ratio (TTM)

2.94

Earnings Yield % (TTM)

9.31%

Earnings Yield % (FWD)

-9.27%

EV / EBITDA (TTM)

6.12

Price / EBITDA (TTM)

9.36

Price / Free Cash Flow (TTM)

7.73

Book Value / Share

$8.86

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$720.24M

Debt to Equity

0.07

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-